Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Materials Chemistry. B
|
April 8, 2026
Stress relaxation timescale and hydrogel network connectivity regulate neural progenitor cell stemness and differentiation
Lauren E Brown, Daphne Bakker, Ping Zhou, et al.
The Journal of Allergy and Clinical Immunology
|
February 15, 2023
Biomarkers in atopic dermatitis
Daphne Bakker, Marjolein de Bruin-Weller, Julia Drylewicz, et al.
JMIR Formative Research
|
July 11, 2025
Developing and Integrating Digital Sources in an Accessible and Sustainable Online Platform for Adolescents and Young Adult Cancer Survivors: Collaborative Design Approach
Carla Vlooswijk, Sophia He Sleeman, Jonas Pluis, et al.
Allergy
|
March 19, 2023
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis
Roselie Achten, Judith Thijs, Marlot van der Wal, et al.
Ocular Immunology and Inflammation
|
February 28, 2023
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile
Roselie Achten, Chantal van Luijk, Judith Thijs, et al.
JAMA Dermatology
|
November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry
Lotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
Allergy
|
July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Lotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Acta Dermato-Venereologica
|
January 31, 2022
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
Roselie E Achten, Chantal Van Luijk, Lisa Van der Rijst, et al.
Clinical and Translational Allergy
|
January 27, 2023
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease
Roselie Achten, Judith Thijs, Marlot van der Wal, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
February 9, 2024
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy
Roselie Achten, Judith Thijs, Marlot van der Wal, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Materials Chemistry. B
|
April 8, 2026
Stress relaxation timescale and hydrogel network connectivity regulate neural progenitor cell stemness and differentiation
Lauren E Brown, Daphne Bakker, Ping Zhou, et al.
The Journal of Allergy and Clinical Immunology
|
February 15, 2023
Biomarkers in atopic dermatitis
Daphne Bakker, Marjolein de Bruin-Weller, Julia Drylewicz, et al.
JMIR Formative Research
|
July 11, 2025
Developing and Integrating Digital Sources in an Accessible and Sustainable Online Platform for Adolescents and Young Adult Cancer Survivors: Collaborative Design Approach
Carla Vlooswijk, Sophia He Sleeman, Jonas Pluis, et al.
Allergy
|
March 19, 2023
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis
Roselie Achten, Judith Thijs, Marlot van der Wal, et al.
Ocular Immunology and Inflammation
|
February 28, 2023
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile
Roselie Achten, Chantal van Luijk, Judith Thijs, et al.
JAMA Dermatology
|
November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry
Lotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
Allergy
|
July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Lotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Acta Dermato-Venereologica
|
January 31, 2022
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
Roselie E Achten, Chantal Van Luijk, Lisa Van der Rijst, et al.
Clinical and Translational Allergy
|
January 27, 2023
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease
Roselie Achten, Judith Thijs, Marlot van der Wal, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
February 9, 2024
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy
Roselie Achten, Judith Thijs, Marlot van der Wal, et al.
Page
of 2